From the FDA Drug Label
The changes in female reproductive organs were considered secondary to the increase in prolactin serum levels The FDA drug label does not directly answer the question of whether Abilify (aripiprazole) can affect prolactin levels in a 20-year-old transgender male. However, it does mention that increased prolactin serum levels were observed in juvenile rats, which led to changes in female reproductive organs.
- Key points:
- The label does not provide direct information on the effect of aripiprazole on prolactin levels in humans, particularly in transgender males.
- The information on prolactin levels is based on animal studies, which may not be directly applicable to humans.
- Prolactin levels may be affected by aripiprazole, but this is not explicitly stated for humans, and more specifically, for a 20-year-old transgender male 1.
From the Research
Abilify (aripiprazole) can lower prolactin levels in a 20-year-old transgender male, and this effect is particularly relevant due to its potential to align with desired hormonal effects in this population. Unlike many other antipsychotic medications that tend to increase prolactin, Abilify has a unique mechanism as a partial dopamine agonist that often results in decreased prolactin levels 2. The typical dose range for Abilify is 5-30 mg daily, with most adults taking 10-15 mg daily.
Key Points to Consider
- The prolactin-lowering effect of Abilify typically begins within weeks of starting treatment and continues throughout therapy 3.
- Abilify helps normalize dopamine signaling in the brain, and dopamine naturally inhibits prolactin secretion from the pituitary gland 4.
- It is essential to discuss concerns about prolactin levels with a healthcare provider, who can monitor levels through blood tests and adjust medication as needed, considering potential interactions with gender-affirming hormone therapy 5.
- A study found that male patients on aripiprazole had a lower risk of suffering an increase in prolactin plasma levels, and aripiprazole had a reduced risk of hyperprolactinemia compared to other antipsychotics 6.
Monitoring and Adjustment
- Regular monitoring of prolactin levels is crucial, especially in patients of childbearing age and those with immune deficiencies 4.
- Healthcare providers should be aware of the potential for hypoprolactinemia as a consequence of taking Abilify and discuss this with patients, particularly those who may be affected by abnormally low prolactin levels 4.